Intel stock extends gains after report of possible U.S. government stake
CHARLOTTE, N.C. - DENTSPLY SIRONA Inc. (NASDAQ:XRAY), a leader in dental products and technologies, has announced the appointment of David Ferguson as Senior Vice President, Global Business Unit Leader, effective last Monday. Ferguson, with a 25-year tenure in the MedTech and healthcare sectors, will oversee the company’s dental product portfolio and report to CEO Simon Campion. The appointment comes as the $3.1 billion market cap company trades near its 52-week low, according to InvestingPro data.
Ferguson’s career includes significant roles at GE Healthcare, Baxter, and Philips, where he has been recognized for his ability to deliver results and manage global product strategy. His most recent position was President of Gore Medical. Ferguson also holds a PhD in Chemistry and has been involved in various leadership and advisory capacities throughout his career.
CEO Simon Campion expressed confidence in Ferguson’s ability to drive business performance and capitalize on strategic opportunities, stating that his expertise will strengthen the company’s market position.
Ferguson shared his enthusiasm for joining Dentsply Sirona and his intent to focus on execution, financial and operational goals, and profitable growth. He emphasized the company’s potential given its broad portfolio in a competitive landscape.
Dentsply Sirona, headquartered in Charlotte, North Carolina, prides itself on a history of innovation and service in the dental industry. The company’s extensive range of dental and oral health products aims to advance patient care and promote safer dental practices.
This strategic appointment is based on a press release statement from DENTSPLY SIRONA Inc.
In other recent news, ZimVie Inc. experienced a downgrade from Needham analysts, who shifted their rating from Buy to Hold. This change reflects concerns about the dental market’s growth potential and weakening U.S. consumer sentiment. Needham’s analysis indicates a cautious outlook for ZimVie, with no significant catalysts expected to drive near-term growth. Meanwhile, DENTSPLY SIRONA has seen several analyst revisions following its recent financial results. Mizuho Securities lowered its price target from $21 to $18, maintaining a Neutral rating, citing slower growth expectations and revised earnings per share estimates for 2025 and 2026. Jefferies also adjusted its price target for DENTSPLY SIRONA to $17, maintaining a Hold rating due to challenges in the dental industry and specific issues with its Byte brand. UBS, however, reaffirmed a Buy rating with a $27 price target, despite the company’s soft first-quarter guidance. Needham reduced its price target for DENTSPLY SIRONA to $23 while keeping a Buy rating, reflecting mixed financial outlooks and recent performance. These developments highlight the varied analyst perspectives on DENTSPLY SIRONA’s future amid industry headwinds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.